8-K
filed June 20, 2023, 7:59 PM ET
ticker ERNA
CIK 0000748592
other material
confidence high
sentiment neutral
materiality 0.15
Eterna Therapeutics shareholders approve all four proposals at 2023 annual meeting
Ernexa Therapeutics Inc.
- Elected five directors: Cherington, Angel, Fiore, Wexler, Singer — each received >2.68M votes for, ~770K broker non-votes.
- Ratified Grant Thornton as auditor for FY 2023: 3.52M for, 23K against, 6K abstain.
- Approved potential issuance of >20% of outstanding shares under Lincoln Park Capital purchase agreement: 2.75M for, 27K against.
- Approved amendment to Restated 2020 Stock Incentive Plan, increasing reserved shares from 680,599 to 980,599: 2.62M for, 160K against.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
Ernexa Therapeutics Inc. shareholders approved Approval, for purposes of complying with Nasdaq Listing Rule 5635(d), to potentially issuance and sell more than 20% of the Company's outstanding common stock pursuant to its purchase agreement with Lincoln Park Capital, LLC at the 2023-06-16 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2023-06-16
Exact text from the filing
Proposal 3 : Approval, for purposes of complying with Nasdaq Listing Rule 5635(d), to potentially issuance and sell more than 20% of the Company’s outstanding common stock pursuant to its purchase agreement with Lincoln Park Capital, LLC : Votes For Votes Against Abstentions Broker Non-Votes 2,751,635 26,798 2,027 769,743
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
Ernexa Therapeutics Inc. shareholders approved Approval of an amendment to the Company's Restated 2020 Stock Incentive Plan to increase the number of shares reserved for issuance from 680,599 shares to 980,599 shares at the 2023-06-16 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2023-06-16
Exact text from the filing
Proposal 4 : Approval of an amendment to the Company’s Restated 2020 Stock Incentive Plan to increase the number of shares reserved for issuance from 680,599 shares to 980,599 shares : Votes For Votes Against Abstentions Broker Non-Votes 2,615,319 160,415 4,726 769,743
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
Ernexa Therapeutics Inc. shareholders approved Election of five directors to the Board of Directors of the Company to hold office until the Company's 2024 Annual Meeting of Stockholders or until their respective successors are elected and qualified at the 2023-06-16 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-06-16
Exact text from the filing
Proposal 1 : Election of five directors to the Board of Directors of the Company to hold office until the Company’s 2024 Annual Meeting of Stockholders or until their respective successors are elected and qualified: Director Votes For Votes Withheld Broker Non-Votes Charles Cherington 2,731,140 49,320 769,743 Matthew Angel 2,761,115 19,345 769,743 Gregory Fiore 2,687,900 92,560 769,743 William Wexler 2,746,291 34,169 769,743 Nicholas J. Singer 2,757,575 22,885 769,743
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
Ernexa Therapeutics Inc. shareholders approved Ratification of the appointment of Grant Thornton LLP as the Company's independent registered public accounting firm for the 2023 fiscal year at the 2023-06-16 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-06-16
Exact text from the filing
Proposal 2 : Ratification of the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the 2023 fiscal year: Votes For Votes Against Abstentions Broker Non-Votes 3,520,765 23,287 6,151 —
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.